Media Coverage: Singapore patients may get greater access to novel cancer drugs under R&D partnership

The Singapore Translational Cancer Consortium (STCC) was inducted as the first Southeast Asian member of the prestigious immunotherapy Centers of Research Excellence (imCORE) Network. The STCC’s leadership was pivotal in advancing translational cancer research in partnership with key national institutions such as National Cancer Centre Singapore and National University Cancer Institute, Singapore.

For Singaporeans, it could mean access to new cancer drugs being tested, while the network will gain access to a diverse pool of Asian trial participants.

Media coverage can be accessed below:

• The Straits Times (Online)

• The Straits Times (Print)

• HealthXchange

• BioSpectrum Asia

For more information, please refer to the following:

• Press release

• Speech by Prof Tan Chorh Chuan